Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

lasmiditan

China flag thumb

Sanofi and Lilly also visited by Chinese authorities

Follows GSK bribery allegations

- PMLiVE

Lilly/ Boehringer’s Lantus biosimilar accepted for EMA review

Moves pharma companies’ version of Sanofi's blockbuster insulin a step closer to approval

- PMLiVE

Medicare puts brake on Lilly’s Alzheimer’s test

Will only reimburse new Alzheimer's diagnostic Amyvid for patients in trials

- PMLiVE

ADA: Lilly’s once-weekly diabetes drug bests Januvia and Byetta

Late-stage trials of dulaglutide show superiority over established brands

- PMLiVE

ADA: Boehringer/ Lilly’s empagliflozin shows blood glucose benefits

Phase III results for diabetes candidate also indicate significant weight loss

- PMLiVE

Safety fears force Lilly to halt BACE inhibitor trial in Alzheimer’s

Patients experience abnormal liver functions in trial

- PMLiVE

NICE knocks back Lilly’s Alimta in new setting

Institute not recommending Lilly’s lung cancer drug for new licence extension

- PMLiVE

Lilly’s Strattera wins new adult ADHD licence in UK

On course for wider EU approval for adults yet to receive treatment

- PMLiVE

Boehringer/ Lilly launch online diabetes management game

Pharma companies aim to raise awareness of type 2 diabetes complications

- PMLiVE

Another setback for Lilly as lymphoma drug fails

Late-stage candidate enzastaurin shows disappointing phase III results

- PMLiVE

Lilly expects to submit five drugs for US approval in 2013

Hopes FDA submissions will help offset patent losses for Zyprexa and Cymbalta

Lilly ramps up social media use

Next phase of LillyPad blog expansion aims at journalists

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links